Cargando…

Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells

Chronic myelogenous leukemia (CML) is a myeloproliferative disease characterized by the BCR-ABL oncogene. Despite the high performance of treatment with tyrosine kinase inhibitors (TKI), about 30% of patients develop resistance to the therapy. To improve the outcomes, identification of new targets o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitrovský, Ondřej, Myslivcová, Denisa, Macháčková-Lopotová, Tereza, Obr, Adam, Čermáková, Kamila, Ransdorfová, Šárka, Březinová, Jana, Klamová, Hana, Žáčková, Markéta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10159124/ https://www.ncbi.nlm.nih.gov/pubmed/37141212 http://dx.doi.org/10.1371/journal.pone.0284876

Ejemplares similares

Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
por: Xu, Zhenshu, et al.
Publicado: (2009)

Expression patterns of microRNAs associated with CML phases and their disease related targets
por: Machová Poláková, Kateřina, et al.
Publicado: (2011)

Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: Indian perspective
por: Ghosh, K
Publicado: (2022)

Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
por: Yoshifuji, Kota, et al.
Publicado: (2022)

Casein Kinase 2 Dependent Phosphorylation of Neprilysin Regulates Receptor Tyrosine Kinase Signaling to Akt
por: Siepmann, Martin, et al.
Publicado: (2010)

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib
por: Cassuto, Ophélie, et al.
Publicado: (2012)

The Bone Phenotype and Pain Response to Pamidronate in Tyrosine Kinase Inhibitor–Treated Chronic Myelogenous Leukemia
por: Lavoie, Declan C T, et al.
Publicado: (2019)

Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
por: Kaehler, Meike, et al.
Publicado: (2021)

Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: A single center experience
por: Bommannan, KB, et al.
Publicado: (2022)

A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors
por: Li, Qing, et al.
Publicado: (2016)

Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining
por: Curik, Nikola, et al.
Publicado: (2021)

Inhibition of abl Oncogene Tyrosine Kinase Induces Erythroid Differentiation of Human Myelogenous Leukemia K562 Cells
por: Honma, Yoshio, et al.
Publicado: (1990)

Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase?
por: Ono, Takaaki
Publicado: (2021)

Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells
por: Okabe, Seiichi, et al.
Publicado: (2023)

Casein kinase signaling in axon regeneration
por: Ayad, Nagi G., et al.
Publicado: (2016)

Editorial: Casein kinases in human diseases
por: Venerando, Andrea, et al.
Publicado: (2022)

Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment
por: Okumura, Lucas M., et al.
Publicado: (2015)

Altered intracellular signaling by imatinib increases the anti‐cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells
por: Hirao, Takuya, et al.
Publicado: (2017)

Myelomastocytic Blast Cell Crisis in Resistant Tyrosine Kinase Inhibitor Chronic Myelogenous Leukemia: Case Report and Review of Literature
por: Martinez-Cordero, Humberto, et al.
Publicado: (2019)

The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability
por: Lobello, Cosimo, et al.
Publicado: (2018)

Protein-N-myristoylation-dependent phosphorylation of serine 13 of tyrosine kinase Lyn by casein kinase 1γ at the Golgi during intracellular protein traffic
por: Kinoshita-Kikuta, Emiko, et al.
Publicado: (2020)

Extramedullary Involvement by Chronic Myelogeneous Leukemia in Five Patients With Unusual Clinicopathologic Features: A Review of the Effectiveness of Tyrosine Kinase Inhibitors
por: Soni, Abha, et al.
Publicado: (2016)

Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia
por: Lei, Hu, et al.
Publicado: (2021)

Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients
por: Rivera, Donna R, et al.
Publicado: (2020)

Casein kinase II is a predominantly nuclear enzyme
Publicado: (1992)

Casein Kinase 2 inhibition sensitizes medulloblastoma to temozolomide
por: Nitta, Ryan T., et al.
Publicado: (2019)

Casein Kinase 2 Signaling in White Matter Stroke
por: Nguyen, Hung, et al.
Publicado: (2022)

The Drosophila Splicing Factor PSI Is Phosphorylated by Casein Kinase II and Tousled-Like Kinase
por: Taliaferro, J. Matthew, et al.
Publicado: (2013)

Crosstalk between casein kinase II and Ste20-related kinase Nak1
por: Cipak, Lubos, et al.
Publicado: (2013)

BY-kinases: Protein tyrosine kinases like no other
por: Hajredini, Fatlum, et al.
Publicado: (2022)

Tyrosine Kinases in Cancer
por: Blau, Olga, et al.
Publicado: (2015)

Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin
por: Obr, Adam, et al.
Publicado: (2014)

Bruton’s Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux
por: Čermáková, Lucie, et al.
Publicado: (2022)

Bosutinib: A Novel Src/Abl Kinase Inhibitor for Chronic Myelogenous Leukemia
por: Steinbach, Alison, et al.
Publicado: (2013)

Immunocytochemical localization of casein kinase II during interphase and mitosis
Publicado: (1991)

Tubulin phosphorylation by casein kinase II is similar to that found in vivo
Publicado: (1987)

Modulation of transcriptional mineralocorticoid receptor activity by casein kinase 2
por: Ruhs, Stefanie, et al.
Publicado: (2017)

Casein kinase 1α: biological mechanisms and theranostic potential
por: Jiang, Shaojie, et al.
Publicado: (2018)

Casein Kinase 1 Epsilon Regulates Glioblastoma Cell Survival
por: Varghese, Robin T., et al.
Publicado: (2018)

Targeting Casein Kinase 1 (CK1) in Hematological Cancers
por: Janovská, Pavlína, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cpatvitv50cbbdmq61vtdgcul9